AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
Key takeaways
- Tezspire’s Phase 3 win positions it as the first approved treatment for EoE, potentially opening a sizable new market for AstraZeneca and Amgen.
- EoE affects >470,000 U.S. patients
- Pre‑market AMGN down 1.49% to $433.80
- Pre‑market AZN down 0.63% to $165.22
What happened
AstraZeneca Plc (AZN) and Amgen Inc. (AMGN) announced that their drug Tezspire (tezepelumab) achieved statistically significant and clinically meaningful improvements in a Phase 3 CROSSING trial for eosinophilic esophagitis (EoE), meeting both co‑primary endpoints of histologic remission and dysphagia reduction, and all key secondary endpoints at week 24, with benefits sustained through week 52.
Why it matters
The results give Tezspire a strong chance to become the first approved therapy for EoE, a disease affecting over 470,000 U.S. patients and growing fivefold since 2009. Successful approval would open a new therapeutic niche for both companies and could drive future sales growth, while also expanding Tezspire’s…
Short-term and longer-term
Short-term. Short‑term traders should watch the next earnings release for any mention of a regulatory filing date and potential pricing strategy.
Longer-term. Longer‑term investors should consider the strategic fit of Tezspire within each company’s portfolio.